{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:54Z","timestamp":1790014734454,"version":"4.0.1"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ebm-journal.org"],"crossmark-restriction":true},"short-container-title":["Exp. Biol. Med."],"abstract":"<jats:p>In recent years, the relationship between the immunosuppressive niche of the bone marrow and therapy resistance in acute myeloid leukemia (AML) has become a research focus. The abnormal number and function of immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), along with the dysfunction and exhaustion of immunological effector cells, including cytotoxic T lymphocytes (CTLs), dendritic cells (DCs) and natural killer cells (NKs), can induce immune escape of leukemia cells and are closely linked to therapy resistance in leukemia. This article reviews the research progress on the relationship between immune cells in the marrow microenvironment and chemoresistance in AML, aiming to provide new ideas for the immunotherapy of AML.<\/jats:p>","DOI":"10.3389\/ebm.2025.10235","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:51:25Z","timestamp":1739274685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Bone marrow immune cells and drug resistance in acute myeloid leukemia"],"prefix":"10.3389","volume":"250","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qulian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"896426","DOI":"10.3389\/fonc.2022.896426","article-title":"Drug resistance mechanisms of acute myeloid leukemia stem cells","volume":"12","author":"Niu","year":"2022","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/bs9.0000000000000092","article-title":"The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia","volume":"3","author":"Shapoorian","year":"2021","journal-title":"Blood Science Baltimore, Md"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.blre.2017.08.010","article-title":"Patient-reported outcomes in acute myeloid leukemia: where are we now?","volume":"32","author":"Buckley","year":"2018","journal-title":"Blood Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"671579","DOI":"10.3389\/fimmu.2021.671579","article-title":"Tr1 cells as a key regulator for maintaining immune homeostasis in transplantation","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4049\/jimmunol.178.1.179","article-title":"Th3 cells in peripheral tolerance. I. Induction of foxp3-positive regulatory T cells by Th3 cells derived from TGF-\u03b2 T cell-transgenic mice","volume":"178","author":"Carrier","year":"2007","journal-title":"The J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.4049\/jimmunol.178.7.4022","article-title":"Cutting edge: IL-2 is essential for TGF-\u03b2-mediated induction of Foxp3+ T regulatory cells","volume":"178","author":"Davidson","year":"2007","journal-title":"The J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"764786","DOI":"10.3389\/fimmu.2021.764786","article-title":"Newly found peacekeeper: potential of CD8+ Tregs for graft-versus-host disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.4049\/jimmunol.177.5.2803","article-title":"Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors","volume":"177","author":"Ford","year":"2006","journal-title":"The J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1385\/ir:35:1:163","article-title":"Double-negative regulatory T cells: non-conventional regulators","volume":"35","author":"Thomson","year":"2006","journal-title":"Immunologic Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/eji.201141808","article-title":"Double negative Treg cells promote nonmyeloablative bone marrow chimerism by inducing T-cell clonal deletion and suppressing NK cell function","volume":"42","author":"Su","year":"2012","journal-title":"Eur J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood.v108.11.759.759","article-title":"Double negative T cells influence TCR VB variablity to induce allotolerance","volume":"108","author":"McIver","year":"2006","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.intimp.2010.11.015","article-title":"Consequences of double negative regulatory T cell and antigen presenting cell interaction on immune response suppression","volume":"11","author":"Ford McIntyre","year":"2011","journal-title":"Int immunopharmacology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/cei.13145","article-title":"Infusion of ex-vivo expanded human TCR-\u03b1\u03b2+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease","volume":"193","author":"Achita","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imm.13178","article-title":"Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes","volume":"160","author":"Ono","year":"2020","journal-title":"Immunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1182\/blood-2013-02-481788","article-title":"Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.ccr-08-3010","article-title":"Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.19746\/j.cnki.issn.1009-2137.2022.06.010","article-title":"Expression of Tregs and IL-35 in peripheral blood of patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Yang","year":"2022","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"B19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/jbm.s221301","article-title":"Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers","volume":"10","author":"Ahmed","year":"2019","journal-title":"J Blood Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.humimm.2015.09.020","article-title":"Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia","volume":"76","author":"Wang","year":"2015","journal-title":"Hum Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25\u2212 naive T cells to CD4+CD25+ regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"The J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/ijc.29563","article-title":"Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts","volume":"137","author":"Tao","year":"2015","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1182\/blood.v128.22.5166.5166","article-title":"Increasing frequency of T cell immunosuppressive receptor expression in CD4+ and CD8+ T cells may related to T cell exhaustion and immunosuppression in patients with AML","volume":"128","author":"Tan","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","article-title":"Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels","volume":"61","author":"Sanchez-Correa","year":"2013","journal-title":"Cytokine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.4103\/0973-1482.187367","article-title":"Associations of interleukin-10 gene polymorphisms with acute myeloid leukemia in human (Egypt)","volume":"14","author":"Rashed","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1182\/blood.v116.21.502.502","article-title":"Membrane associated TGF-\u03b21 on leukemia blast-derived microvesicles in sera of acute myeloid leukemia patients suppresses NK cell function","volume":"116","author":"Boyiadzis","year":"2010","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"112958","DOI":"10.1016\/j.intimp.2024.112958","article-title":"Prognostic impact of enhanced CD96 expression on NK cells by TGF-\u03b21 in AML","volume":"141","author":"Zhang","year":"2024","journal-title":"Int immunopharmacology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3390\/cancers15205086","article-title":"MicroRNA expression patterns reveal a role of the TGF-\u03b2 family signaling in AML chemo-resistance","volume":"15","author":"Reichelt","year":"2023","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2022015474","article-title":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post\u2013allo-HSCT","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.7150\/thno.50928","article-title":"Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2019-122206","article-title":"Phenotypic characterization of the immune landscape in the bone marrow of patients with acute myeloid leukemia (AML) using MultiOmyxTM hyperplexed immunofluorescence assay","volume":"134","author":"Au","year":"2019","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1182\/blood.v118.21.3611.3611","article-title":"IL-2 stimulated treg inhibit in vitro expansion of haploidentical natural killer (NK) cells, which is partially overcome with an IL-2-diphtheria toxin fusion protein in vivo","volume":"118","author":"Cooley","year":"2011","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e12281","DOI":"10.1371\/journal.pone.0012281","article-title":"Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGF\u03b2","volume":"5","author":"Frimpong-Boateng","year":"2010","journal-title":"PloS one"},{"key":"B36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/tan.13872","article-title":"The immune checkpoints Cytotoxic T lymphocyte antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia","volume":"96","author":"Radwan","year":"2020","journal-title":"Hla"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.31557\/apjcp.2024.25.5.1777","article-title":"Prognostic effect of CTLA4\/LAG3 expression by T-cells subsets on acute myeloid leukemia patients","volume":"25","author":"El Dosoky","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"key":"B39","first-page":"84","article-title":"Dysregulated expression of CD28 and CTLA-4 molecules in patients with acute myeloid leukemia and possible association with development of graft versus host disease after hematopoietic stem cell transplantation","volume":"10","author":"Ramzi","year":"2019","journal-title":"Int J Organ Transplant Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/nejmoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3389\/fimmu.2020.01710","article-title":"PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia","volume":"11","author":"Dong","year":"2020","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/08880018.2017.1383542","article-title":"Checkpoint inhibition in pediatric hematologic malignancies","volume":"34","author":"Davis","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol and Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"111765","DOI":"10.1016\/j.intimp.2024.111765","article-title":"Lactate acid promotes PD-1+ Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia","volume":"130","author":"Zhang","year":"2024","journal-title":"Int immunopharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"The J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"The J Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1182\/blood-2018-99-117784","article-title":"LAG3 promotes acute myeloid leukemia-induced immune suppression","volume":"132","author":"Abdelhakim","year":"2018","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2329024","DOI":"10.1080\/16078454.2024.2329024","article-title":"TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia","volume":"29","author":"Alqahtani","year":"2024","journal-title":"Hematology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.cd-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (pembro) and azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 Years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2643-3230.bcd-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood-2019-131494","article-title":"Azacitidine (aza) with nivolumab (nivo), and aza with nivo + ipilimumab (ipi) in relapsed\/refractory acute myeloid leukemia: a non-randomized, prospective, phase 2 study","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2018-99-115382","article-title":"Post allogeneic stem cell transplant (SCT) cyclophosphamide improves progression free survival (PFS) in pts with AML\/MDS treated with CTLA-4 or PD-1 blockade prior to SCT","volume":"132","author":"Oran","year":"2018","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1002\/ajh.26043","article-title":"A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia","volume":"96","author":"Zheng","year":"2021","journal-title":"Am J Hematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/bloodadvances.2021005240","article-title":"Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome","volume":"6","author":"Gerds","year":"2022","journal-title":"Blood Adv"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14653240500499507","article-title":"CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system","volume":"8","author":"Zhong","year":"2006","journal-title":"Cytotherapy"},{"key":"B65","doi-asserted-by":"publisher","first-page":"57.9","DOI":"10.4049\/jimmunol.202.supp.57.9","article-title":"An agonist TIGIT mab suppresses regulatory T cell activity via an IL-2-mediated mechanism","volume":"202","author":"Jones","year":"2019","journal-title":"The J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.ccr-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00280-023-04627-3","article-title":"Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors","volume":"94","author":"Yamamoto","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother Adv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3389\/fimmu.2018.02227","article-title":"Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells","volume":"9","author":"Han","year":"2018","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"152804","DOI":"10.1016\/j.imbio.2024.152804","article-title":"Increased co-expression of ICOS and PD-1 predicts poor overall survival in patients with acute myeloid leukemia","volume":"229","author":"Pan","year":"2024","journal-title":"Immunobiology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12885-020-06961-8","article-title":"Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia","volume":"20","author":"Wan","year":"2020","journal-title":"BMC cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","article-title":"Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model","volume":"469","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/1078-0432.ccr-23-2654","article-title":"Targeting CCL2\/CCR2 signaling overcomes MEK inhibitor resistance in acute myeloid leukemia","volume":"30","author":"Modak","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/cbin.11246","article-title":"HIF-1\u03b1 forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells","volume":"44","author":"Zhu","year":"2020","journal-title":"Cell Biol Int"},{"key":"B76","doi-asserted-by":"publisher","first-page":"110934","DOI":"10.1016\/j.celrep.2022.110934","article-title":"HIF-1\u03b1 is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma","volume":"39","author":"Miska","year":"2022","journal-title":"Cell Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"113009","DOI":"10.1016\/j.biopha.2022.113009","article-title":"Role of Acute Myeloid Leukemia (AML)-Derived exosomes in tumor progression and survival","volume":"150","author":"Amin","year":"2022","journal-title":"Biomed and Pharmacother"},{"key":"B78","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lfs.2019.02.003","article-title":"Leukemia-derived exosomes induced IL-8 production in bone marrow stromal cells to protect the leukemia cells against chemotherapy","volume":"221","author":"Chen","year":"2019","journal-title":"Life Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"14684","DOI":"10.1038\/s41598-017-14661-w","article-title":"Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia","volume":"7","author":"Hong","year":"2017","journal-title":"Scientific Rep"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"The Oncologist"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.ccr-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1182\/blood-2019-125966","article-title":"A phase 1 study of flotetuzumab, a CD123 x CD3 DART\u00ae protein, combined with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory acute myeloid leukemia","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"Tps7563","DOI":"10.1200\/jco.2020.38.15_suppl.tps7563","article-title":"A phase I\/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed\/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies","volume":"38","author":"Daver","year":"2020","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-021-01163-6","article-title":"SIRP\u03b1-\u03b1CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells","volume":"14","author":"Tahk","year":"2021","journal-title":"J Hematol and Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428194.2021.1975192","article-title":"CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies","volume":"63","author":"Wilson","year":"2022","journal-title":"Leuk and Lymphoma"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.2147\/cmar.s260825","article-title":"Plasmacytoid dendritic cell infiltration in acute myeloid leukemia","volume":"12","author":"Zhu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2019-126478","article-title":"Mechanisms of tolerance induction through T regulatory cells during chemotherapy-mediated immunogenic cell death in acute myeloid leukemia","volume":"134","author":"Ocadlikova","year":"2019","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1182\/blood.v120.21.4787.4787","article-title":"Indoleamine 2,3-dioxygenase (Ido) is associated with high incidence of chemorefractory disease in acute myeloid leukemia (AML) patients","volume":"120","author":"Parisi","year":"2012","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cpt.2023.11.001","article-title":"Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer","volume":"2","author":"Sarangi","year":"2024","journal-title":"Cancer Pathogenesis Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3324\/haematol.13113","article-title":"High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome","volume":"93","author":"Chamuleau","year":"2008","journal-title":"Haematologica"},{"key":"B92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1073\/pnas.0711106105","article-title":"Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation","volume":"105","author":"Onishi","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B94","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/imcb.12484","article-title":"Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy","volume":"99","author":"Wilson","year":"2021","journal-title":"Immunol and Cell Biol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.v97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e25771","DOI":"10.4161\/onci.25771","article-title":"Trial watch: dendritic cell-based interventions for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13014-016-0635-5","article-title":"Feasibility study of DCs\/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer","volume":"11","author":"Zhang","year":"2016","journal-title":"Radiat Oncol (London, England)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.21873\/anticanres.12464","article-title":"WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study","volume":"38","author":"Yanagisawa","year":"2018","journal-title":"Anticancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"152237","DOI":"10.1016\/j.imbio.2022.152237","article-title":"Leukemia derived dendritic cell (DCleu) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells","volume":"227","author":"Pepeldjiyska","year":"2022","journal-title":"Immunobiology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"107965","DOI":"10.1016\/j.intimp.2021.107965","article-title":"Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia","volume":"99","author":"Yang","year":"2021","journal-title":"Int immunopharmacology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1146\/annurev-biochem-011520-102754","article-title":"HLAs, TCRs, and KIRs, a triumvirate of human cell-mediated immunity","volume":"89","author":"Djaoud","year":"2020","journal-title":"Annu Rev Biochem"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/blood.2019002887","article-title":"External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails","volume":"135","author":"Schetelig","year":"2020","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"665541","DOI":"10.3389\/fimmu.2021.665541","article-title":"Natural killer cell subpopulations and inhibitory receptor dynamics in myelodysplastic syndromes and acute myeloid leukemia","volume":"12","author":"Cianga","year":"2021","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-020-01302-6","article-title":"Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia","volume":"20","author":"Dai","year":"2021","journal-title":"Mol Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"49","DOI":"10.19746\/j.cnki.issn.1009-2137.2022.01.009","article-title":"The expression and function of NK cells in patients with acute myeloid leukemia","volume":"30","author":"Liu","year":"2022","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"B107","doi-asserted-by":"publisher","first-page":"101407","DOI":"10.1016\/j.smim.2020.101407","article-title":"NK cells in the tumor microenvironment: prognostic and theranostic impact. Recent advances and trends","volume":"48","author":"Russick","year":"2020","journal-title":"Semin Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"683381","DOI":"10.3389\/fimmu.2021.683381","article-title":"Optimizing NK cell-based immunotherapy in myeloid leukemia: abrogating an immunosuppressive microenvironment","volume":"12","author":"Kaweme","year":"2021","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12967-022-03589-z","article-title":"Heme oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48","volume":"20","author":"Zhang","year":"2022","journal-title":"J translational Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/10428194.2021.1984454","article-title":"Characteristics and clinical correlation of TIM-3 and PD-1\/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia","volume":"63","author":"Chajuwan","year":"2022","journal-title":"Leuk and Lymphoma"},{"key":"B111","doi-asserted-by":"publisher","first-page":"730970","DOI":"10.3389\/fimmu.2021.730970","article-title":"Chronic IL-15 stimulation and impaired mTOR signaling and metabolism in natural killer cells during acute myeloid leukemia","volume":"12","author":"Bou-Tayeh","year":"2021","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","volume":"16","author":"Baraga\u00f1o Raneros","year":"2015","journal-title":"Genes Immun"},{"key":"B113","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/1753425918800200","article-title":"When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection","volume":"24","author":"Beliz\u00e1rio","year":"2018","journal-title":"Innate Immun"},{"key":"B114","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","article-title":"CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients","volume":"190","author":"Wang","year":"2018","journal-title":"Clin Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"B117","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"key":"B118","doi-asserted-by":"publisher","first-page":"751834","DOI":"10.3389\/fonc.2021.751834","article-title":"Acute myeloid leukemia epigenetic immune escape from nature killer cells by ICAM-1","volume":"11","author":"Xiao","year":"2021","journal-title":"Front Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1042\/cs20191170","article-title":"Acute myeloid leukemia immune escape by epigenetic CD48 silencing","volume":"134","author":"Wang","year":"2020","journal-title":"Clin Sci"},{"key":"B120","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/eji.201747128","article-title":"KIR downregulation by IL-12\/15\/18 unleashes human NK cells from KIR\/HLA-I inhibition and enhances killing of tumor cells","volume":"48","author":"Ewen","year":"2018","journal-title":"Eur J Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3109\/14653249.2011.563292","article-title":"Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function","volume":"13","author":"Satwani","year":"2011","journal-title":"Cytotherapy"},{"key":"B122","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-derived cd123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of cd123-targeted chimeric antigen receptor T-cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-139609","article-title":"Results from the phase I clinical studies evaluating cyad-01, a first-generation NKG2D CAR T-cell product in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B128","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cel Res and Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"720501","DOI":"10.3389\/fonc.2021.720501","article-title":"From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies","volume":"11","author":"Lu","year":"2021","journal-title":"Front Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","article-title":"Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00262-020-02490-2","article-title":"Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition","volume":"69","author":"Greiner","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1889822","DOI":"10.1080\/2162402x.2021.1889822","article-title":"TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients","volume":"10","author":"Rakova","year":"2021","journal-title":"Oncoimmunology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/cam4.4661","article-title":"Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T\u2010cells and regulatory T\u2010cells in TP53mutated acute myeloid leukemia","volume":"11","author":"Abolhalaj","year":"2022","journal-title":"Cancer Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s12094-022-03065-6","article-title":"The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook","volume":"25","author":"Song","year":"2022","journal-title":"Clin Translational Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.2147\/cmar.s205296","article-title":"T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"11","author":"Xue","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2018-99-114864","article-title":"Pembrolizumab enhances the anti-leukemia activity of antigen specific cytotoxic T lymphocytes","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood-2021-149318","article-title":"Pembrolizumab in combination with antigen-specific cytotoxic T lymphocytes enhances killing of acute myeloid leukemia","volume":"138","author":"Gibson","year":"2021","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2019-128044","article-title":"A phase I study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous T cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation","volume":"134","author":"Morris","year":"2019","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1038\/onc.2010.367","article-title":"Up for Mischief? IL-17\/Th17 in the tumour microenvironment","volume":"29","author":"Maniati","year":"2010","journal-title":"Oncogene"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1683347","DOI":"10.1080\/2162402x.2019.1683347","article-title":"The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia","volume":"9","author":"Xu","year":"2020","journal-title":"Oncoimmunology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.4049\/jimmunol.0902813","article-title":"Tumor microenvironments direct the recruitment and expansion of human Th17 cells","volume":"184","author":"Su","year":"2010","journal-title":"The J Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"328","DOI":"10.19746\/j.cnki.issn.1009-2137.2021.02.004","article-title":"Regulation effect of myeloid leukemia No.1 Chinese herb medicine prescription combined with chemotherapy on Th17 cells in bone marrow of patients with acute myeloid leukemia","volume":"29","author":"Zhang","year":"2021","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"B144","doi-asserted-by":"publisher","first-page":"882004","DOI":"10.3389\/fgene.2022.882004","article-title":"High expression of B4GALT1 is associated with poor prognosis in acute myeloid leukemia","volume":"13","author":"Ren","year":"2022","journal-title":"Front Genet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3389\/fimmu.2018.01274","article-title":"Increased regulatory T cells in peripheral blood of acute myeloid leukemia patients rely on tumor necrosis factor (TNF)-\u03b1-TNF receptor-2 pathway","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/cas.12459","article-title":"Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia","volume":"105","author":"Han","year":"2014","journal-title":"Cancer Sci"},{"key":"B147","doi-asserted-by":"publisher","first-page":"34","DOI":"10.21474\/ijar01\/14359","article-title":"Clinical expression of th17 related cytokinesin acute myeloid leukemia patients: a prospective descriptive study","volume":"10","author":"Dhakal","year":"2022","journal-title":"Int J Adv Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1182\/blood-2018-99-111671","article-title":"Epigenetic therapy targets Th1\/Th17 polarization to reversing immune evasion and treating leukemia relapse post allogeneic stem cell transplantation in non-APL AML patients","volume":"132","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.actbio.2022.11.007","article-title":"Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia","volume":"157","author":"Wang","year":"2023","journal-title":"Acta Biomater"},{"key":"B150","doi-asserted-by":"publisher","first-page":"113794","DOI":"10.1016\/j.celrep.2024.113794","article-title":"ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion","volume":"43","author":"Bassani","year":"2024","journal-title":"Cell Rep"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/cancers13061203","article-title":"Immunosuppressive cell subsets and factors in myeloid leukemias","volume":"13","author":"Swatler","year":"2021","journal-title":"Cancers"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/jcm10132788","article-title":"Myeloid-derived suppressor cells and mesenchymal stem\/stromal cells in myeloid malignancies","volume":"10","author":"Kapor","year":"2021","journal-title":"J Clin Med"},{"key":"B153","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.20050715","article-title":"Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma","volume":"202","author":"Rodriguez","year":"2005","journal-title":"The J Exp Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"The J Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2007.12.004","article-title":"Abrogation of TGF\u03b2 signaling in mammary carcinomas recruits gr-1+CD11b+ myeloid cells that promote metastasis","volume":"13","author":"Yang","year":"2008","journal-title":"Cancer cell"},{"key":"B156","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2015.00107","article-title":"Myeloid derived suppressor cells in chronic myeloid leukemia","volume":"5","author":"Giallongo","year":"2015","journal-title":"Front Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/cells9061559","article-title":"Immunotherapy in myeloproliferative diseases","volume":"9","author":"Braun","year":"2020","journal-title":"Cells"},{"key":"B158","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1002\/cam4.3360","article-title":"Immunosuppressive role of CD11b+ CD33+ HLA-DR- myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia","volume":"9","author":"Hyun","year":"2020","journal-title":"Cancer Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.18632\/oncotarget.1504","article-title":"Indoleamine 2,3-dioxygenase 1 (Ido1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia","volume":"5","author":"Folgiero","year":"2014","journal-title":"Oncotarget"},{"key":"B160","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers"},{"key":"B162","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4274\/tjh.galenos.2022.2022.0137","article-title":"Monocytic myeloid-derived suppressor cells but not monocytes predict poor prognosis of acute myeloid leukemia","volume":"39","author":"Ren","year":"2022","journal-title":"Turkish J Hematol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1158\/0008-5472.can-20-0024","article-title":"Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2\/akt\/mTOR signaling","volume":"80","author":"Tohumeken","year":"2020","journal-title":"Cancer Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"741911","DOI":"10.3389\/fcell.2021.741911","article-title":"mTOR signaling regulates the development and therapeutic efficacy of PMN-MDSCs in acute GVHD","volume":"9","author":"Li","year":"2021","journal-title":"Front Cel Dev Biol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e13158","DOI":"10.1111\/sji.13158","article-title":"Cytarabine-induced TNF\u03b1 promotes the expansion and suppressive functions of myeloid-derived suppressor cells in acute myeloid leukaemia","volume":"95","author":"Bai","year":"2022","journal-title":"Scand J Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood.v128.22.703.703","article-title":"Acute myeloid leukemia cells export c-myc in extracellular vesicles driving a proliferation of immune-suppressive myeloid-derived suppressor cells","volume":"128","author":"Pyzer","year":"2016","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1016\/j.bbmt.2014.11.290","article-title":"Myeloid derived suppressor cells (MDSC)-like acute myeloid leukemia (AML) cells are associated with resistance to cytotoxic effects of autologous (auto) T-lymphocytes (CTLs)","volume":"21","author":"Mehta","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B168","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40164-024-00516-4","article-title":"Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation","volume":"13","author":"Notarantonio","year":"2024","journal-title":"Exp Hematol and Oncol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"e1469594","DOI":"10.1080\/2162402x.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B170","doi-asserted-by":"publisher","first-page":"e14012","DOI":"10.1200\/jco.2015.33.15_suppl.e14012","article-title":"The Ido inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro","volume":"33","author":"Jochems","year":"2015","journal-title":"J Clin Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clml.2018.12.005","article-title":"A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (Ido) enzyme INCB024360 in patients with myelodysplastic syndromes","volume":"19","author":"Komrokji","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.v124.21.1113.1113","article-title":"Dendritic cell vaccination in acute leukemia patients induces reduction of myeloid-derived suppressor cells: immunological analysis of a pilot study","volume":"124","author":"Ogasawara","year":"2014","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1182\/blood.v122.21.3885.3885","article-title":"Myeloid leukemias directly suppress T cell proliferation through STAT3 and arginase pathways","volume":"122","author":"Miner","year":"2013","journal-title":"Blood"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:51:36Z","timestamp":1739274696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":173,"alternative-id":["10.3389\/ebm.2025.10235"],"URL":"https:\/\/doi.org\/10.3389\/ebm.2025.10235","relation":{},"ISSN":["1535-3699"],"issn-type":[{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"article-number":"10235"}}